Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
Status:
Completed
Trial end date:
2021-10-19
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, randomized, double blind, vehicle controlled, parallel group, proof of
concept study that will include participants with stasis dermatitis without active skin
ulceration, who will receive crisaborole ointment 2% or vehicle twice daily for 6 weeks.